Imalumab
Imalumab
Imalumab (pronunciation: i-ma-lu-mab) is a monoclonal antibody designed for the treatment of various autoimmune diseases and inflammatory diseases.
Etymology
The name "Imalumab" follows the World Health Organization's guidelines for the International Nonproprietary Names (INN) of monoclonal antibodies. The suffix "-mab" indicates it is a monoclonal antibody, while the infix "-l-" suggests it is related to the immune system.
Function
Imalumab works by targeting and inhibiting the function of BAFF, also known as B-cell activating factor, a protein that promotes the survival and growth of B cells. By blocking BAFF, Imalumab can reduce the number of harmful B cells that contribute to the symptoms of autoimmune and inflammatory diseases.
Clinical Trials
Imalumab has undergone clinical trials to evaluate its safety and efficacy in treating various conditions, including rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome. However, the results have been mixed, and further research is needed to determine the optimal use of this drug.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Inflammatory disease
- BAFF
- B cells
- Clinical trials
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Sjögren's syndrome
External links
- Medical encyclopedia article on Imalumab
- Wikipedia's article - Imalumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski